Kazia Therapeutics jumped 51.74% in after-hours trading Tuesday after reporting a rare immune-complete response in a patient.

The Brisbane Cancer Conference is a premier oncology meeting that brings together leading international researchers, clinicians and industry experts working in the fields of translational oncology, ...

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

D printed hydrogel expanders use controlled buckling and low pressure to generate new soft tissue while preserving viability ...

This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces a growing body of scientific ...

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious ...

TKI-based regimens remain the primary approach for metastatic renal cell carcinoma after immune checkpoint inhibitor therapy, ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disorder globally, with a rising ...

Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent ...